Evaxion Biotech A/S expected to post a loss of 39 cents a share - Earnings Preview

Evaxion A/S

14/08/2024 12:05

* Evaxion Biotech A/S  EVAX.OQ   EVAX.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 14
for the period ending June 30 2024
    * The Copenhagen Denmark-based   company is expected to
report
revenue of $52 thousand, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Evaxion Biotech A/S is
for a
loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evaxion
Biotech
A/S is $8.00​, above​ its last closing price of $2.71. ​​​

This summary was machine generated August 14 at 11:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)